Last reviewed · How we verify

NCT03653858: FORESEE III

Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression

Status unknown NA Last updated 3 November 2022
What this trial tests

NA trial testing Vercise GEVIA deep brain stimulation (DBS) system in Treatment-resistant Depression in 47 participants. Status unknown.

Timeline
3 September 2018
Primary endpoint
2 June 2025
2 June 2025

Quick facts

Lead sponsorUniversity Hospital Freiburg
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment47
Start date3 September 2018
Primary completion2 June 2025
Estimated completion2 June 2025
Sites2 locations across France, Germany

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital Freiburg

Who can join

Adults 20 to 75, any sex, with Treatment-resistant Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this multicenter, randomized, sham-controlled, double blind (patient and observer blinded) clinical trial is to assess the antidepressant effect of Deep Brain Stimulation (DBS) in patients with treatment resistant major depression using the Boston Scientific implantable Vercise™ GEVIA™ DBS system compared to sham.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Deep Brain Stimulation for the Management of Refractory Neurological Disorders: A Comprehensive Review.
    Rissardo JP, Vora NM, Tariq I, Mujtaba A, et al · · 2023 · cited 17× · PMID 38004040 · DOI 10.3390/medicina59111991
  2. "The Heart Asks Pleasure First"-Conceptualizing Psychiatric Diseases as <i>MAINTENANCE</i> Network Dysfunctions through Insights from slMFB DBS in Depression and Obsessive-Compulsive Disorder.
    Coenen VA, Schlaepfer TE, Sajonz BEA, Reinacher PC, et al · · 2022 · cited 12× · PMID 35447971 · DOI 10.3390/brainsci12040438
  3. A narrative review on invasive brain stimulation for treatment-resistant depression.
    Dandekar MP, Diaz AP, Rahman Z, Silva RH, et al · · 2022 · cited 7× · PMID 34468549 · DOI 10.1590/1516-4446-2021-1874
  4. Normalized affective responsiveness following deep brain stimulation of the medial forebrain bundle in depression.
    Kilian HM, Schiller B, Meyer-Doll DM, Heinrichs M, et al · · 2024 · cited 4× · PMID 38191528 · DOI 10.1038/s41398-023-02712-y
  5. Joint Anatomical, Histological, and Imaging Investigation of the Midbrain Target Region for Superolateral Medial Forebrain Bundle Deep Brain Stimulation.
    Coenen VA, Zielinski JM, Sajonz BEA, Reinacher PC, et al · · 2025 · cited 2× · PMID 39527932 · DOI 10.1159/000541834
  6. ACNP 58<sup>th</sup> Annual Meeting: Poster Session III.
    · 2019 · cited 2× · PMID 31801974 · DOI 10.1038/s41386-019-0547-9
  7. Best practices for clinical trials of deep brain stimulation for neuropsychiatric indications.
    Tremblay-McGaw AG, Hamlat EJ, Becker NC, Astudillo Maya DA, et al · · 2025 · cited 1× · PMID 40309667 · DOI 10.3389/fnhum.2025.1572972

Verify or expand the search:

Other recruiting trials for Treatment-resistant Depression

Currently open trials in the same condition.

Other University Hospital Freiburg trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03653858.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing